Modulating protein ubiquitination via proteasome inhibition represents a promising target for cancer therapy, owing to the higher sensitivity of cancer cells to the cytotoxic effects of proteasome inhibition. Here we show that CEP-18770 is a novel orally-active inhibitor of the chymotrypsin-like activity of the proteasome which down-modulates the NF-κB activity and the expression of several 
Introduction
The ubiquitin-proteasome pathway plays a key role in protein processing and degradation, regulating crucial transduction pathways for cell growth and survival, including cell cycle control, transcriptional regulation, cellular stress responses, and antigen presentation 1, 2 . Numerous investigators have demonstrated that proteasome inhibition results in the disruption of normal homeostatic mechanisms, and that cancer cells are more likely to undergo apoptosis following proteasome inhibition compared to normal cells [3] [4] [5] [6] . It is known that proteasome inhibition can reverse the aberrant changes that perpetuate proliferation and block apoptosis pathways in cancer cells. In fact, treatment of cancer cells with proteasome inhibitors results in the stabilization of p21 and p27 7, 8 , as well as inhibition of nuclear factor-kappaB (NF-κB)-mediated transcription 9, 10 . The NF-κB pathway is activated in a variety of tumor types and often deregulated in chemotherapyresistant cells, suggesting that NF-κB activation plays a role in cancer cell survival and chemoresistance, and that NF-κB inhibition via proteasome inhibition can sensitize transformed cells to apoptosis [11] [12] [13] .
The prevalent sensitivity of transformed cells to proteasome inhibitors and the successful design of clinical protocols, with tolerable although relatively narrow therapeutic indices, have made the proteasome a novel and promising target for cancer treatment 2, 6 . Clinical validation for the application of proteasome inhibition as a therapeutic strategy was achieved with Velcade ® (bortezomib; Millenium Pharmaceuticals Inc.), a modified dipeptidyl boronic acid intravenously administered slowly-reversible inhibitor of the chymotrypsin-like activity of the 26S mammalian proteasome 4, 5, 14 . On the basis of pivotal clinical trials, bortezomib has proven efficacious as single agent for the treatment of multiple myeloma (MM), non-Hodgkin, and mantle cell lymphoma patients [15] [16] [17] . Although the toxicity profile of bortezomib is quite well controlled in clinical settings, its side effects include peripheral neuropathy, orthostatic hypotension, pyrexia, cardiac and pulmonary disorders, gastrointestinal adverse events, myelosuppression, thrombocytopenia, asthenia, and pain 18, 19 . Consequently, there is a need for the identification of proteasome inhibitors with enhanced tolerability and safety profiles. Salinosporamide A (NPI-0052) extracted from a marine actinomycete bacteria is a novel orally-active proteasome inhibitor shown to effectively induce apoptosis in tumor cells of MM 20 and chronic lymphocytic leukemia (CLL), while displaying a lower toxic activity to bone marrow-derived stromal cells (BMSC) compared to bortezomib 21 . An irreversible epoxy-ketone peptidyl inhibitor of all three proteasome proteolytic sites (PR-171) is currently in clinical evaluation (Phase I) for advanced solid tumors and refractory hematological malignancies 22 .
In the present study, we describe the in vitro and in vivo biological characterization of CEP-18770, 
Material and Methods

Enzyme and cellular biochemical activity profiles against the mammalian proteasome
The proteasome inhibitory activity of CEP-18770 and bortezomib were evaluated in an isolated human erythrocyte proteasome fluorimetric kinetic assay of chymotrypsin-like proteasome activity 23 . Experiments were performed in triplicate.
Cell lines and primary cell cultures and treatments
Human multiple myeloma (MM) cell lines CMA-03, JJN3, H929, KMM1, KMS11, KMS18, KMS27, SKMM1, U266, RPMI-8226, human chronic myelogenous leukemia cell line K562, T-cell leukemic line MOLT-4, human anaplastic lymphoma ALK positive TS cells were used 24, 25 . MM myeloid, and T-cell lines were grown at 37°C in 5% CO 2 humidified air in RPMI 1640 medium (Cambrex, Verviers, Belgium) or in Iscove's Modified Dulbecco's Medium (IMDM) (Cambrex, Verviers, Belgium), respectively, all supplemented with 10% of fetal calf serum (FCS), without growth factors or alternatively with IL-6 10 ng/mL (CMA 03) 26 . Cells were seeded at 5 x 10 5 cells/mL for the proteasome inhibitor treatments. Normal human microvascular endothelial cells from derma (HMEC) were immortalized by infection with a replication-defective adeno-5/SV40
virus as previously described 27 . The tumor-derived endothelial cells (TEC) have previously been described 28 . HMEC and TEC cell lines were established and maintained in culture in Endothelial cell Basal Medium (EBM) supplemented with epidermal growth factor (10 ng/ml), hydrocortisone
(1 mg/mL), bovine brain extract (Cambrex Bioscience, Baltimore, MD, USA), and 10% FCS.
Peripheral blood mononuclear cells (PBMC) were obtained from healthy individuals after FicollHypaque density separation. Bone marrow mononuclear cells (BMNC) were used to establish longterm BMSC cultures from multiple myeloma patients (7) and from non-cancenerous individuals (5 and enriched by magnetic bead based positive selection (CD138 MicroBeads, Miltenyi Biotech Inc., Bergisch Gladbach, Germany). Purified PC were seeded (1 x 10 6 cells/mL) on a 50% confluent BMSC monolayer in 6-well plates and maintained in IMDM supplemented with 20% FCS and IL-6 10 ng/mL. PC were then treated with proteasome inhibitors for 72 h.
Flow cytometry analyses of apoptosis
Apoptosis was measured by flow cytometry with the mitochondrion-permeable, voltage sensitive dye tetrametylrodamine methyl ester (TMRM) (Molecular Probes, Eugene, OR, USA) as described 24 .
Proliferation and viability assays
The effect of proteasome inhibitors on mononuclear cell viability was measured using a methylthiazolyldiphenyl-tetrazolium bromide (MTT) based assay as detailed using the following formula: percentage cell viability = (OD of the experimental samples / mean OD of the control) x 100 29 .
Western Blotting
The following primary antibodies were used for Western blotting as previously described 30 : rabbit anti-phospho IKBα (Ser32), anti-cleaved caspase 3, anti-cleaved caspase 7, and anti-cleaved 
Electrophoretic Mobility Shift Assay (EMSA)
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Aliquots of total extracts (12 μg protein/sample) in 0.1% Triton X-100 lysis buffer (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 1 mM Na 3 VO 4 , and 1 mM PMSF and protease inhibitors) were incubated with [ 32 P]-labeled κB DNA probe in binding buffer (10 mM Tris-HCl, pH 7.5, 1mM EDTA, 5% glycerol) for 30 min at room temperature. Quantitative evaluation of NF-κB-DNA probe complex formation was determined as previously described 30 .
RT-PCR
Total RNA from BMSC cultured in 10 cm plates (passage 4 to 6) and after treatment with proteasome inhibitors (60 h) were extracted using the RNAeasy Mini Kit (Qiagen, Hilden, Germany 
CEP-18770 targets NF-κB activity
The most compelling rationale for the therapeutic use of proteasome inhibitors in oncology relies on their ability to inhibit the nuclear factor-κB (NF-κB) transcriptional activity resulting in the reduced expression of several target genes [11] [12] [13] . Since proteasome inhibitors modulate the activation of NF-κB primarily by blocking IκBα degradation 
CEP-18770 inhibits endothelial cell survival, proliferation and morphogenesis
Bone marrow-derived angiogenesis is a hallmark of MM progression 35, 36 . Inhibition of NF-κB-mediated regulation of angiogenic cytokines and adhesion molecules (ICAM-1, VCAM-1, and VEGF) and modulation of tumor cell-endothelial cell interactions, are, in part, responsible for the anti-angiogenic activity of bortezomib 19, 35 . The anti-angiogenic effects of CEP-18770 were evaluated in normal human microvascular endothelial cells from derma (HMEC) and from renal carcinoma (TEC) 37 treated with CEP-18770 and bortezomib. Apoptosis and cell growth were used as read-outs. As shown in Figure 5A and 5B, 20 nM CEP-18770 inhibited proliferation and triggered levels of apoptosis comparable to 10 nM bortezomib, in both HMEC and TEC, as assessed by mitochondrial depolarization and crystal violet staining assays at 24 and 48 h, (Figure 5C-D) .
CEP-18770 inhibits M-CSF-RANKL-mediated osteoclastogenesis
A unique feature of MM patients is a sustained bone destruction; a major source of morbidity (severe bone pain and pathological fractures) due primarily to an increased osteoclast activity 31, 38 .
Since NF-kB plays a central role in osteoclast formation, blocking NF-kB activity is a potential strategy for inhibition of osteoclast formation. To investigate whether CEP-18770 and bortezomib could similarly affect the osteoclastogenic potential, PBMCs from normal donors were induced to differentiate into osteoclasts for 10 days in presence of recombinant human M-CSF (25 ng/ml), followed by RANKL (30 ng/ml) activation, for additional 5 days. Numerous, large tartrate-resistant acid phosphatase (TRAP) positive osteoclasts were reproducibly generated (osteoclasts average number/well = 195 ± 127). Consistent with earlier studies 39, 40 , both CEP-18770 or bortezomib added simultaneously with RANKL dramatically suppressed osteoclastogenesis (Figure 5E-F) .
Importantly, CEP-18770 resulted in a more pronounced inhibition of osteoclast formation (13 ± 8; p<0.003 versus bortezomib) compared to that of bortezomib (83 ± 100; p<0.06 versus controls).
These findings indicate that CEP-18770 is a potent inhibitor of RANKL-mediated osteoclastogenesis in vitro.
Efficacy profile of CEP-18770 in human MM models in mice
The in vivo anti-tumor efficacy of CEP-18770 compared to bortezomib was examined first in a series of studies using the human MM RPMI 8226 s.c. xenograft model in SCID mice following Table 2 . These data indicate comparable and similarly robust median survival benefits for twice weekly administration of CEP-18770 (at 3 and 4 mg/kg i.v.) and bortezomib (at 1.2 mg/kg i.v.), as well as high dose dexamethasone administration.
Melphalan treatment was associated with the greatest survival benefit relative to vehicle control mice (p<0.001).
Discussion
The ubiquitin proteasome pathway represents a promising target for cancer therapy, owing to the higher sensitivity of cancer cells to cytotoxic effects of proteasome inhibition compared to normal cells 6, 19 . To date, bortezomib is the only proteasome inhibitor currently approved for human use, despite relevant side effects, including peripheral neuropathy, orthostatic hypotension, pyrexia, gastrointestinal symptoms, thrombocytopenia, asthenia, and pain 14, 15 . Since targeting the ubiquitinproteasome system is anticipated as a powerful strategy for the treatment of a large spectrum of human malignancies, the discovery of new anti-proteasome drugs with a more favorable profile and enhanced tolerability is recommended 20, 22, 41 .
A primary rationale for the therapeutic use of proteasome inhibitors in oncology relies on their ability to inhibit NF-κB activity. The inhibition of NF-κB activity reduces the expression of several target genes regulating cell proliferation and survival of cancer cells [11] [12] [13] . Therefore, the modulation of NF-κB activity offers significant therapeutic results in numerous malignancies, including MM, 
